Key points from article :
Researchers are moving closer to realizing the clinical potential of senolytic drugs for healthy aging.
Senolytic agents target senescent cells, which accumulate with age and are associated with chronic conditions.
Mayo Clinic's Kogod Center on Aging developed the first senolytic drugs to target harmful senescent cells.
A new screening platform has been developed for finding additional senolytic drugs, including HSP90 inhibitors.
The platform will help researchers quickly identify drugs that target aging processes for clinical intervention.
Senolytic drugs show potential impact on a wide range of diseases related to aging.
Clinical trials for senolytic drugs face unique challenges, such as testing long-term end points.
Mayo Clinic is using new clinical trial paradigms to test the effects of senolytic drugs on various age-related conditions.
Additional geriatricians with research training are needed to lead future clinical trials.
The goal is to achieve the same success in humans as in preclinical animal models to prevent or delay age-related conditions.
